Tech Company Financing Transactions
Compass Therapeutics Funding Round
OrbiMed, Alexandria Venture Investments and Biomatics Capital Partners participated in a $49 million Series A venture round for Compass Therapeutics. The round was announced on 7/13/2018.
Transaction Overview
Company Name
Announced On
7/13/2018
Transaction Type
Venture Equity
Amount
$49,000,000
Round
Series A
Investors
Proceeds Purpose
This financing will enable the company to advance its next-generation antibody-based therapeutics into the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 1st St. 3rd Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Comprehensively drugging the tumor-immune synapse with human antibodies against over 50 cell surface and soluble targets. Combining and engineering the best antibody leads in our proprietary Targeted Immunomodulation platform approach.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Schuetz Thomas
Chief Operating Officer
Jeb Ledell
Chief Scientific Officer
Piotr Bobrowicz
VP - Engineering
Michael Schmidt
VP - Human Resources
Sara Mannle
VP - Manufacturing
Greg Zarbis-Papastoitsis
Browse more venture capital transactions:
Prev: 7/12/2018: Tamr venture capital transaction
Next: 7/13/2018: ORIG3N venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs